Trials / Completed
CompletedNCT02558894
Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Detailed description
This is a Phase II, open-label, multi-center study to determine the efficacy and safety of MEDI4736 evaluated as single agent or in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed on fluoropyrimidine containing or gemcitabine-containing first-line chemotherapy.This study will consist of Part A, lead-in, as well as a possible expansion Part B.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI4736 monotherapy | MEDI4736 via IV infusion. |
| DRUG | tremelimumab+MEDI4736 | tremelimumab+MEDI4736 via IV infusion. |
Timeline
- Start date
- 2015-11-16
- Primary completion
- 2017-06-15
- Completion
- 2017-06-15
- First posted
- 2015-09-24
- Last updated
- 2018-08-02
- Results posted
- 2018-08-02
Locations
21 sites across 6 countries: United States, Canada, Germany, Netherlands, South Korea, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02558894. Inclusion in this directory is not an endorsement.